# A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

> **NCT07635316** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 4023 (estimated)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07635316
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-12
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-02-25
- **Target enrollment:** 4023 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635316, "A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07635316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*